Interleukin-2-mediated CD4 T-cell activation correlates highly with effective serological and T-cell responses to SARS-CoV-2 vaccination in people living with HIV.
Humans
CD4-Positive T-Lymphocytes
/ immunology
HIV Infections
/ immunology
Interleukin-2
Male
Middle Aged
Female
COVID-19
/ immunology
SARS-CoV-2
/ immunology
Antibodies, Viral
/ blood
Lymphocyte Activation
Adult
COVID-19 Vaccines
/ immunology
CD4 Lymphocyte Count
Vaccination
Immunoglobulin G
/ blood
Antibodies, Neutralizing
/ blood
COVID‐19
T cell
cytokine
people living with HIV
serology
vaccine
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
28
06
2024
received:
03
03
2024
accepted:
09
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
26
7
2024
Statut:
ppublish
Résumé
People living with HIV (PLWH) despite having an appreciable depletion of CD4
Substances chimiques
Interleukin-2
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29820Subventions
Organisme : European Union's Horizon 2020 research and innovation program
ID : 101016167
Informations de copyright
© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.
Références
Wu N, Joyal‐Desmarais K, Ribeiro PAB, et al. Long‐term effectiveness of COVID‐19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta‐analysis up to December, 2022. Lancet Respir Med. 2023;11:439‐452.
Lin DY, Gu Y, Xu Y, et al. Association of primary and booster vaccination and prior infection with SARS‐CoV‐2 infection and severe COVID‐19 outcomes. JAMA. 2022;328:1415‐1426.
Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA‐1273 SARS‐CoV‐2 vaccine. N Engl J Med. 2021;384:403‐416.
Li Y, Wang X, Jin J, et al. T‐cell responses to SARS‐CoV‐2 omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine. J Med Virol. 2022;94:3998‐4004.
Auerbach JD, Forsyth AD, Davey C, Hargreaves JR. Living with COVID‐19 and preparing for future pandemics: revisiting lessons from the HIV pandemic. Lancet HIV. 2023;10:e62‐e68.
Jin J, Wang X, Carapito R, Moog C, Su B. Advances in research on COVID‐19 vaccination for people living with HIV. Infect Dis Immun. 2022;2:213‐218.
Alrubayyi A, Gea‐Mallorquí E, Touizer E, et al. Characterization of humoral and SARS‐CoV‐2 specific T cell responses in people living with HIV. Nat Commun. 2021;12:5839.
Nkosi T, Chasara C, Papadopoulos AO, et al. Unsuppressed HIV infection impairs T cell responses to SARS‐CoV‐2 infection and abrogates T cell cross‐recognition. eLife. 2022;11. doi:10.7554/eLife.78374
Brumme ZL, Mwimanzi F, Lapointe HR, et al. Humoral immune responses to COVID‐19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. NPJ Vaccines. 2022;7:28.
Antinori A, Cicalini S, Meschi S, et al. Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current CD4 T‐lymphocyte count. Clin Infect Dis. 2022;75:552.
Chun HM, Milligan K, Agyemang E, et al. A systematic review of COVID‐19 vaccine antibody responses in people with HIV. Open Forum Infect Dis. 2022;9:ofac579.
Vergori A, Tavelli A, Matusali G, et al. SARS‐CoV‐2 mRNA vaccine response in people living with HIV according to CD4 count and CD4/CD8 ratio. Vaccines. 2023;11:1664.
Zhou Q, Liu Y, Zeng F, Meng Y, Liu H, Deng G. Correlation between CD4 T‐Cell counts and seroconversion among COVID‐19 vaccinated patients with HIV: a Meta‐Analysis. Vaccines. 2023;11:789.
Benet S, Blanch‐Lombarte O, Ainsua‐Enrich E, et al. Limited humoral and specific T‐Cell responses after SARS‐CoV‐2 vaccination in PWH with poor immune reconstitution. J Infect Dis. 2022;226:1913‐1923.
Verburgh ML, van Pul L, Grobben M, et al. Robust vaccine‐induced as well as hybrid B‐ and T‐Cell immunity across SARS‐CoV‐2 vaccine platforms in people with HIV. Microbiol Spectr. 2023;11:e0115523.
Woldemeskel BA, Karaba AH, Garliss CC, et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV). Clin Infect Dis. 2022;74:1268‐1270.
Alexandrova Y, Yero A, Mboumba Bouassa RS, et al. SARS‐CoV‐2 vaccine‐induced T‐Cell response after three doses in people living with HIV on antiretroviral therapy compared to seronegative controls (CTN 328 COVAXHIV Study). Viruses. 2023;15:575.
Augello M, Bono V, Rovito R, Tincati C, d'Arminio Monforte A, Marchetti G. Six‐month immune responses to mRNA‐1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS‐CoV‐2 infection. AIDS. 2023;37:1503‐1517.
Zhou Z, Barrett J, He X. Immune imprinting and implications for COVID‐19. Vaccines. 2023;11:875.
Huang CQ, Vishwanath S, Carnell GW, Chan ACY, Heeney JL. Immune imprinting and next‐generation coronavirus vaccines. Nat Microbiol. 2023;8:1971‐1985.
Blankson JN. Bivalent COVID‐19 vaccines: can the original antigenic sin be forgiven? J Infect Dis. 2023;227:1221‐1223.
Azzini AM, Canziani LM, Davis RJ, et al. How European research projects can support vaccination strategies: the case of the ORCHESTRA project for SARS‐CoV‐2. Vaccines. 2023;11:1361.
Lee N, Jeong S, Lee SK, et al. Quantitative analysis of Anti‐N and Anti‐S antibody titers of SARS‐CoV‐2 infection after the third dose of COVID‐19 vaccination. Vaccines. 2022;10:1143.
Gupta A, et al Host immunological responses facilitate development of SARS‐CoV‐2 mutations in patients receiving monoclonal antibody treatments. J Clin Invest. 2023. doi:10.1172/JCI166032
Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post‐cytometric complex multivariate datasets. Cytometry, Part A. 2011;79:167‐174.
Yeh YHJ, Ho YC. Shock‐and‐kill versus block‐and‐lock: targeting the fluctuating and heterogeneous HIV‐1 gene expression. Proc Natl Acad Sci. 2021;118. doi:10.1073/pnas.2103692118
Gong C, Song X, Li X, Lu L, Li T. Immunological changes after COVID‐19 vaccination in an HIV‐positive patient. Int J Infect Dis. 2022;117:230‐232.
Crotty S. A brief history of T cell help to B cells. Nat Rev Immunol. 2015;15:185‐189.
Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4(+) T cells in immunity to viruses. Nat Rev Immunol. 2012;12:136‐148.
Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117‐122.
Gallais F, Velay A, Nazon C, et al. Intrafamilial exposure to SARS‐CoV‐2 associated with cellular immune response without seroconversion, France. Emerging Infect Dis. 2021;27:113‐121.
Ford GS, Barnhart B, Shone S, Covey LR. Regulation of CD154 (CD40 ligand) mRNA stability during T cell activation. Journal Immunol. 1999;162:4037‐4044.
Imai N, Tawara I, Yamane M, Muraoka D, Shiku H, Ikeda H. CD4(+) T cells support polyfunctionality of cytotoxic CD8(+) T cells with memory potential in immunological control of tumor. Cancer Sci. 2020;111:1958‐1968.
Cohen KW, Linderman SL, Moodie Z, et al. Longitudinal analysis shows durable and broad immune memory after SARS‐CoV‐2 infection with persisting antibody responses and memory B and T cells. Cell Reports Medicine. 2021;2:100354.
Vega‐Magaña N, Muñoz‐Valle JF, Peña‐Rodríguez M, et al. Specific T‐cell immune response to SARS‐CoV‐2 spike protein over time in naïve and SARS‐CoV‐2 previously infected subjects vaccinated with BTN162b2. Vaccines. 2022;10:1117.
Arunachalam PS, Scott MKD, Hagan T, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021;596:410‐416.
Cooper T, Woodward B, Alom S, Harky A. Coronavirus disease 2019 (COVID‐19) outcomes in HIV/AIDS patients: a systematic review. HIV Med. 2020;21:567‐577.
Morrocchi E, Pighi C, Pascucci GR, et al. Perinatally human immunodeficiency virus‐infected adolescents and young adults demonstrate distinct BNT162b2 messenger RNA coronavirus disease 2019 vaccine immunogenicity. Clin Infect Dis. 2022;75:S51‐S60.
Mondi A, Cimini E, Colavita F, et al. COVID‐19 in people living with HIV: clinical implications of dynamics of the immune response to SARS‐CoV‐2. J Med Virol. 2021;93:1796‐1804.
Jabea Ekabe C, Asaba Clinton N, Agyei EK, Kehbila J. Role of apoptosis in HIV pathogenesis. Adv Virol. 2022;2022:1‐10.
Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV‐specific CD4+ T cells. Nature. 2002;417:95‐98.
Brites‐Alves C, Luz E, Netto EM, et al. Immune activation, proinflammatory cytokines, and conventional risks for cardiovascular disease in HIV patients: a case‐control study in Bahia, Brazil. Front Immunol. 2018;9:1469.
Kinter AL, Bende SM, Hardy EC, Jackson R, Fauci AS. Interleukin 2 induces CD8+ T cell‐mediated suppression of human immunodeficiency virus replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci. 1995;92:10985‐10989.
Cote‐Sierra J, Foucras G, Guo L, et al. Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci. 2004;101:3880‐3885.
Ross SH, Cantrell DA. Signaling and function of Interleukin‐2 in T lymphocytes. Annu Rev Immunol. 2018;36:411‐433.
Ballesteros‐Tato A, León B, Graf BA, et al. Interleukin‐2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity. 2012;36:847‐856.
Adachi Y, Oyaizu N, Than S, McCloskey TW, Pahwa S. IL‐2 rescues in vitro lymphocyte apoptosis in patients with HIV infection: correlation with its ability to block culture‐induced down‐modulation of Bcl‐2. The Journal of Immunology. 1996;157:4184‐4193.
Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin‐2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med. 1995;332:567‐575.
Raeber ME, Sahin D, Karakus U, Boyman O. A systematic review of interleukin‐2‐based immunotherapies in clinical trials for cancer and autoimmune diseases. EBioMedicine. 2023;90:104539.
ORIGINAL antigenic sin. N Engl J Med. 1958;258:10161017.
Kelvin AA, Zambon M. Influenza imprinting in childhood and the influence on vaccine response later in life. Euro Surveill. 2019;24. doi:10.2807/1560-7917.ES.2019.24.48.1900720
Takeuchi JS, Fukunaga A, Yamamoto S, et al. SARS‐CoV‐2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study. Sci Rep. 2022;12:15447.
Zaffina S, Alteri C, Ruggiero A, et al. Induction of immune response after SARS‐CoV‐2 mRNA BNT162b2 vaccination in healthcare workers. J Virus Erad. 2021;7:100046.
Jin J, Wang X, Li Y, et al. Weak SARS‐CoV‐2‐specific responses of TIGIT‐expressing CD8 + T cells in people living with HIV after a third dose of a SARS‐CoV‐2 inactivated vaccine. Chin Med J. 2023;136:2938‐2947.
Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV‐1 infection. J Acquir Immune Defic Syndr. 2002;29:346‐355.